TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36826476

Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg on day 1 and day 14)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: [89Zr]-rituximab PET imaging
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: [89Zr]-rituximab SUVmean
Number of subjects: 21
Study: 36826514

Group type: EXPERIMENTAL
Intervention: Porcine dentin-derived graft material (Ivory Dentin Graft™)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Commercial bone-derived graft material
Number of subjects: 36
Study: 36826589

Group type: EXPERIMENTAL
Intervention: Overperforming hospitals
Number of subjects: 3902

Group type: COMPARATOR
Intervention: Underperforming hospitals
Number of subjects: 3902
Study: 36826820

Group type: EXPERIMENTAL
Intervention: Epirubicin (75 mg/m2) and paclitaxel (175 mg/m2) every 3 weeks for 6 cycles (EP regimen)
Number of subjects: 813

Group type: COMPARATOR
Intervention: Epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) every 3 weeks for 4 cycles followed by paclitaxel (175 mg/m2) every 3 weeks for 4 cycles (EC-P regimen)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Epirubicin plus paclitaxel (EP regimen)
Number of subjects: 813

Group type: COMPARATOR
Intervention: Epirubicin and cyclophosphamide followed by paclitaxel (EC-P regimen)
Number of subjects: 813
Study: 36826834

Group type: EXPERIMENTAL
Intervention: Intensive diabetes management (automated insulin delivery system)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Standard care (continuous glucose monitor)
Number of subjects: 113
Study: 36826844

Group type: EXPERIMENTAL
Intervention: Verapamil (n=47)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (n=41)
Number of subjects: 88
Study: 36826976

Group type: EXPERIMENTAL
Intervention: Mobile app plus VR group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mobile app-only group
Number of subjects: 80
Study: 36826995

Group type: EXPERIMENTAL
Intervention: MEDI-570 (monoclonal antibody against ICOS) administered intravenously every 3 weeks for up to 12 cycles at doses ranging from 0.01 to 3 mg/kg.
Number of subjects: 23
Study: 36826996

Group type: EXPERIMENTAL
Intervention: Open-Source Automated Insulin Delivery AndroidAPS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36827003

Group type: EXPERIMENTAL
Intervention: Smokers with generalized periodontitis (SGP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Smokers with healthy periodontium (SHP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nonsmokers with generalized periodontitis (NGP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nonsmokers with healthy periodontium (NHP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Generalized periodontitis groups (SGP, NGP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study: 36827018

Group type: EXPERIMENTAL
Intervention: Selenium treatment
Number of subjects: 1
Study: 36827327

Group type: EXPERIMENTAL
Intervention: Home-based ART (hbART) consisting of 3 home-visits in a 3-month period by a certified male study nurse ART provider.
Number of subjects: 700

Group type: COMPARATOR
Intervention: Facility-based ART (fbART) involving counselling at the male participant's home or a nearby preferred location, followed by escort to the local health facility.
Number of subjects: 700
Study: 36827328

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal antigen Rapid Diagnostic Tests (RDT)
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Saliva RT-PCR
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal (NP) RT-PCR
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Any test (RDT, saliva PCR, NP PCR)
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: STANDARD-Q® Ag test
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Panbio™ Ag test
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: COVID-VIRO® Ag test
Number of subjects: 928
Study: 36827396

Group type: EXPERIMENTAL
Intervention: Neutrophil-to-lymphocyte ratio (NLR)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Platelet-to-lymphocyte ratio (PLR)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Advanced Lung cancer Inflammation Index (ALI)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Depression severity
Number of subjects: 186
Study: 36827440

Group type: EXPERIMENTAL
Intervention: HIV prevention readiness measure (HPRM)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Self-efficacy subscale of HPRM
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: PrEP disclosure subscale of HPRM
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Social support subscale of HPRM
Number of subjects: 315
Study: 36827620

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 0
Study: 36827715

Group type: EXPERIMENTAL
Intervention: Illustrated communication materials
Number of subjects: 100
Study: 36827750

Group type: EXPERIMENTAL
Intervention: Intact umbilical cord milking (UCM)
Number of subjects: 1730
Study: 36827840

Group type: EXPERIMENTAL
Intervention: Primary tumor STn expression above the median
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: PLN STn expression
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Primary tumor MUC1 expression
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Primary tumor MUC4 expression
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Correlation of Tn and STn expression
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Correlation of Tn and MUC1 expression
Number of subjects: 139
Study: 36827856

Group type: EXPERIMENTAL
Intervention: fALFF in the central executive network (CEN)
Number of subjects: 132

Group type: COMPARATOR
Intervention: ReHo in the ventral visual pathway (VVP)
Number of subjects: 132

Group type: COMPARATOR
Intervention: FC in temporal-sensorimotor regions
Number of subjects: 132
Study: 36827906

Group type: EXPERIMENTAL
Intervention: Higher objective SLE impact scores over follow-up
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: SLE impact scores
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Rate of change in epigenetic age
Number of subjects: 171
Study: 36828030

Group type: EXPERIMENTAL
Intervention: Endoscopic vacuum therapy (EVT)
Number of subjects: 27
Study: 36828201

Group type: EXPERIMENTAL
Intervention: Everolimus (EVL) and low-dose tacrolimus (LD-TAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose tacrolimus (TAC) and mycophenolate mofetil (MMF)
Number of subjects: 0
Study: 36828283

Group type: EXPERIMENTAL
Intervention: French AmbUlatory Cesarean Section
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard cesarean delivery
Number of subjects: 116
Study: 36828343

Group type: COMPARATOR
Intervention: Normoglycemic (glycemia 2.2 to 8.3 mmol/L)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Hypoglycemic (at least 1 measurement <2.2 mmol/L)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Hyperglycemic (at least 1 measurement >8.3 mmol/L)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Glycemic lability (at least 1 episode of hypoglycemia and 1 episode of hyperglycemia)
Number of subjects: 545
Study: 36828619

Group type: EXPERIMENTAL
Intervention: Primary intraocular lens (IOL) implantation
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Initial anterior vitrectomy
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Microcornea
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: CC family history
Number of subjects: 351
Study: 36828643

Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg every 4 weeks (Q4W)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg at week 0, week 4, then every 8 weeks (Q8W)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: guselkumab (Q4W)
Number of subjects: 739

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 739
Study: 36828650

Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL) intervention
Number of subjects: 157

Group type: COMPARATOR
Intervention: Home-sent patient information (control group)
Number of subjects: 157
Study: 36828654

Group type: EXPERIMENTAL
Intervention: Colchicine plus high-intensity rosuvastatin in addition to standard of care
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 250
Study: 36828681

Group type: EXPERIMENTAL
Intervention: Early therapeutic intervention for indolent ATLL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 0
Study: 36828719

Group type: EXPERIMENTAL
Intervention: PCV20 and QIV coadministration
Number of subjects: 1796

Group type: COMPARATOR
Intervention: Separate Administration of QIV and PCV20
Number of subjects: 1796
Study: 36828828

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36828925

Group type: EXPERIMENTAL
Intervention: Tocilizumab (IV) for 6 months
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Abatacept (subcutaneous) for 12 months
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Baseline PDUS scores
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Other disease assessments (DAS28 and CDAI)
Number of subjects: 70
Study: 36828945

Group type: EXPERIMENTAL
Intervention: Dietary cysteine intake
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Knee extensors eccentric peak torque
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: One-repetition maximum in back squat exercise
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Glutathione peroxidase (GPx) activity
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Muscle GSSG
Number of subjects: 45
Study: 36829104

Group type: EXPERIMENTAL
Intervention: Propofol (0.5 mg·kg)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 36829108

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) with pulse amplitude ratio (PAR) measurement
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (non LHF group)
Number of subjects: 73
Study: 36829135

Group type: EXPERIMENTAL
Intervention: Arteriovenous graft (AVG)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Arteriovenous fistula (AVF)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: AVG
Number of subjects: 262

Group type: COMPARATOR
Intervention: AVF
Number of subjects: 262
Study: 36829154

Group type: EXPERIMENTAL
Intervention: Iruplinalkib 180 mg orally once daily for a 21-day cycle with a 7-day lead-in phase at 60 mg orally once daily.
Number of subjects: 146
Study: 36829179

Group type: EXPERIMENTAL
Intervention: Usual care plus structured diabetes self-management education program
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 22
Study: 36829237

Group type: EXPERIMENTAL
Intervention: Fit Together intervention using the Playbook implementation platform
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study: 36829240

Group type: EXPERIMENTAL
Intervention: Active tDCS (20-min, 2-mA, 10 sessions during 5 consecutive weekdays)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham tDCS (20-min, 2-mA, 10 sessions during 5 consecutive weekdays)
Number of subjects: 60
Study: 36830710

Group type: EXPERIMENTAL
Intervention: Lipidomic analyses of synovial fluids from patients with chronic joint pain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lipid levels in synovial fluid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LPC16:0 levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other choline-containing lipids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective lipid species in synovial fluid
Number of subjects: 0
Study: 36830825

Group type: EXPERIMENTAL
Intervention: Frameless CyberKnife SRS, doses of 70 to 105 Gy delivered in a single fraction.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Frameless CyberKnife SRS, doses equal to or less than 85 Gy.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Frameless CyberKnife SRS, doses of 95 and 100 Gy.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Frameless CyberKnife SRS, doses below 90 Gy.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Frameless CyberKnife SRS.
Number of subjects: 23
Study: 36831483

Group type: EXPERIMENTAL
Intervention: Radical fimbriectomy (RF)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Radical fimbriectomy (RF) followed by delayed oophorectomy
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Delayed oophorectomy
Number of subjects: 121
Study: 36831516

Group type: EXPERIMENTAL
Intervention: Wire-guided localization (WGL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radioactive techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wire-free localization
Number of subjects: 0
Study: 36831658

Group type: EXPERIMENTAL
Intervention: Hippotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional supportive care
Number of subjects: 0
Study: 36831709

Group type: EXPERIMENTAL
Intervention: Lower Body Positive Pressure (LBPP) Treadmill Training
Number of subjects: 9
Study: 36832093

Group type: EXPERIMENTAL
Intervention: PRRT
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Post-SRETV_WB and ΔSRETV_WB
Number of subjects: 39
Study: 36833192

Group type: EXPERIMENTAL
Intervention: CAH-X treatment
Number of subjects: 0
Study: 36833293

Group type: EXPERIMENTAL
Intervention: Whole exome sequencing (WES) expanded to trio sequencing
Number of subjects: 1

Group type: COMPARATOR
Intervention: Molecular karyotyping
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Trio WES
Number of subjects: 1
Study: 36833589

Group type: EXPERIMENTAL
Intervention: 8-week high intensity online physical exercise intervention combined with online group meetings and supported by an activity watch
Number of subjects: 19
Study: 36833793

Group type: EXPERIMENTAL
Intervention: Personalized computerized cognitive training (CCT) for 8 weeks
Number of subjects: 73
Study: 36834170

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)-guided laparoscopic/robotic pelvic lymphadenectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard systematic lymphadenectomy
Number of subjects: 0
Study: 36834268

Group type: EXPERIMENTAL
Intervention: Active VeNS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham VeNS
Number of subjects: 60
Study: 36834329

Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation (CS) programme
Number of subjects: 308

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 308
Study: 36834367

Group type: EXPERIMENTAL
Intervention: Epidural Steroid Injection through a transforaminal approach (ESI TF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36836101

Group type: EXPERIMENTAL
Intervention: DCM-HFpEF patients
Number of subjects: 911

Group type: COMPARATOR
Intervention: DCM-HFrEF patients
Number of subjects: 911
Study: 36839324

Group type: EXPERIMENTAL
Intervention: Isoflavones and enterolignans dietary intake assessment through 24 h and 48 h dietary recalls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urine and plasma samples analysis for genistein, daidzein, equol, and enterolactone
Number of subjects: 0
Study: 36839882

Group type: EXPERIMENTAL
Intervention: Near-infrared photoimmunotherapy (NIR-PIT)
Number of subjects: 0
Study: 36840749

Group type: EXPERIMENTAL
Intervention: Everolimus 5 mg QD and Sorafenib 200 mg BID (intermittent schedule)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cholangiocarcinomas (intermittent schedule)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Gynecological adenocarcinomas (intermittent schedule)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intermittent dosing schedules
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: EVE 10 mg QD and SOR 400 mg BID (intermittent schedules)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Dose reductions
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Dose-limiting toxicities
Number of subjects: 43
Study: 36840793

Group type: EXPERIMENTAL
Intervention: Echocardiography performed by intensivists
Number of subjects: 53

Group type: COMPARATOR
Intervention: Echocardiography performed by gastroenterologists
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Echocardiography parameters (visual LVEF, subaortic VTI, E wave velocity)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Presence of pleural effusion and hemodynamic profiles (hypovolemic, hyperkinetic, intermediate)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 28-day mortality
Number of subjects: 53
Study: 36840825

Group type: EXPERIMENTAL
Intervention: Early RRT initiation strategy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Delayed RRT initiation strategy
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Presence of septic shock
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Higher mean arterial pressure
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Beta-lactam trough concentration above 4 times the MIC
Number of subjects: 112
Study: 36841085

Group type: EXPERIMENTAL
Intervention: Presence of diabetic retinopathy (DR)
Number of subjects: 1758

Group type: COMPARATOR
Intervention: No diabetic retinopathy (DR)
Number of subjects: 1758
Study: 36841141

Group type: EXPERIMENTAL
Intervention: Rifampicin (RIF)
Number of subjects: 210
Study: 36841318

Group type: EXPERIMENTAL
Intervention: Goreisan at a dose of 7.5 g daily on top of usual care
Number of subjects: 2192

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 2192
Study: 36841351

Group type: EXPERIMENTAL
Intervention: Nemiralisib
Number of subjects: 5
Study: 36841360

Group type: EXPERIMENTAL
Intervention: Biologic treatment eligibility assessment
Number of subjects: 97

Group type: COMPARATOR
Intervention: Systemic corticosteroids (SCS) use
Number of subjects: 97

Group type: COMPARATOR
Intervention: Oral corticosteroids (OCS) use
Number of subjects: 97

Group type: COMPARATOR
Intervention: Asthma control assessment
Number of subjects: 97

Group type: COMPARATOR
Intervention: Health-related quality of life (HRQoL) assessment using SGRQ
Number of subjects: 97

Group type: COMPARATOR
Intervention: Symptom burden assessment
Number of subjects: 97
Study: 36841444

Group type: EXPERIMENTAL
Intervention: Low Glycemic Index Profile (LGIP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: High Glycemic Index Profile (HGIP)
Number of subjects: 25
Study: 36841502

Group type: EXPERIMENTAL
Intervention: BCG vaccine (Moreau or Moscow strains)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Moreau strain of BCG vaccine
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: BCG vaccine
Number of subjects: 264
Study: 36841506

Group type: EXPERIMENTAL
Intervention: Prebiotic (FOS+GOS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 24
Study: 36841540

Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg intravenously every 2 weeks for up to 1 year)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 36841633

Group type: EXPERIMENTAL
Intervention: Vena cava filters (VCFs) implanted in 1421 patients
Number of subjects: 1429
Study: 36841672

Group type: EXPERIMENTAL
Intervention: Therapeutic approaches for TP53 mutated MDS and AML patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal testing strategies for TP53 mutations
Number of subjects: 0
Study: 36841723

Group type: EXPERIMENTAL
Intervention: V114 (15-valent pneumococcal conjugate vaccine)
Number of subjects: 1191

Group type: COMPARATOR
Intervention: PCV13 (13-valent pneumococcal conjugate vaccine)
Number of subjects: 1191
Study: 36841758

Group type: EXPERIMENTAL
Intervention: DS-1594a·HCl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DS-1594a·succinate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DS-1594a·HCl and DS-1594a·succinate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DS-1594a
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cytarabine
Number of subjects: 0
Study: 36841762

Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg/day
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Combination (exercise + liraglutide)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous exercise
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 36841770

Group type: EXPERIMENTAL
Intervention: Ving Tsun sticking-hand training
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 36841773

Group type: EXPERIMENTAL
Intervention: Active transspinal stimulation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham transspinal stimulation
Number of subjects: 45
Study: 36841790

Group type: EXPERIMENTAL
Intervention: Probiotics (Peifeikang, Live Combined Bifidobacterium, 210 mg per capsule, twice a day, four capsules each time)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract)
Number of subjects: 220
Study: 36841794

Group type: EXPERIMENTAL
Intervention: Esketamine combined with pregabalin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline and placebo capsules
Number of subjects: 0
Study: 36841796

Group type: EXPERIMENTAL
Intervention: EOB-MRI
Number of subjects: 101
Study: 36841886

Group type: EXPERIMENTAL
Intervention: Weight Loss intervention (Loss group)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Weight Stability intervention (Stability group)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Bibliotherapy (Control group)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Self-reported smoking cessation
Number of subjects: 305
Study: 36841997

Group type: EXPERIMENTAL
Intervention: Primary closure (Group A) - skin closed with interrupted polypropylene sutures
Number of subjects: 50

Group type: COMPARATOR
Intervention: Secondary closure (Group B) - wound dressed with saline-soaked gauze and allowed to heal by secondary intention
Number of subjects: 50
Study: 36842024

Group type: EXPERIMENTAL
Intervention: Brandt-Daroff exercises
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Half-Somersault exercises
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20